<DOC> 
<DOCNO>1030911_opinion_story_2352364.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Opinion
		 Thursday, September 11, 2003 				 EMERGENCY PROVISIONS
 															- Document Excerpts from the August 30, 2003, decision  of WTO member states on legal changes to allow import of cheaper  generic drugs by poorer countries 				 	 In need of help 																								Having regard to paragraphs 1, 3 and 4 of Article IX of the Marrakesh Agreement Establishing the World Trade Organization...																								Conducting the functions of the Ministerial Conference in the interval between meetings pursuant to paragraph 2 of Article IV of the WTO Agreement; Noting the Declaration on the TRIPS Agreement and Public Health and, in particular, the instruction of the Ministerial Conference to the Council for TRIPS contained in paragraph 6 of the Declaration to find an expeditious solution to the problem of the difficulties that WTO Members with insufficient or no manufacturing capacities in the pharmaceutical sector could face in making effective use of compulsory licensing under the TRIPS Agreement and to report to the General Council before the end of 2002;																								Recognizing, where eligible importing Members seek to obtain supplies under the system set out in this Decision, the importance of a rapid response to those needs consistent with the provisions of this Decision;																								Noting that, in the light of the foregoing, exceptional circumstances exist justifying waivers from the obligations set out in paragraphs (f) and (h) of Article 31 of the TRIPS Agreement with respect to pharmaceutical products; 																								Decides as follows: 																								1. For the purposes of this Decision: (a) pharmaceutical product means any patented product, or product manufactured through a patented process, of the pharmaceutical sector needed to address the public health problems as recognized in paragraph 1 of the Declaration. It is understood that active ingredients necessary for its manufacture and diagnostic kits needed for its use would be included; 																								(b) eligible importing Member means any least-developed country Member, and any other Member that has made a notification to the Council for TRIPS of its intention to use the system as an importer, it being understood that a Member may notify at any time that it will use the system in whole or in a limited way, for example only in the case of a national emergency or other circumstances of extreme urgency or in cases of public non-commercial use. 																								It is noted that some Members will not use the system set out in this Decision as importing Members and that some other Members have stated that, if they use the system, it would be in no more than situations of national emergency or other circumstances of extreme urgency; (c) exporting Member means a Member using the system set out in this Decision to produce pharmaceutical products for, and export them to, an eligible importing Member. 																								2. The obligations of an exporting Member under Article 31 (f) of the TRIPS Agreement shall be waived with respect to the grant by it of a compulsory licence to the extent necessary for the purposes of production of a pharmaceutical product(s) and its export to an eligible importing Member(s) in accordance with the terms set out below in this paragraph: 																								(a) the eligible importing Member(s) has made a notification to the Council for TRIPS, that: (i) specifies the names and expected quantities of the product(s) needed (5); (ii) confirms that the eligible importing Member in question, other than a least developed country Member, has established that it has insufficient or no manufacturing capacities in the pharmaceutical sector for the product(s) in question in one of the ways set out in the Annex to this Decision; TO BE CONCLUDED
</TEXT> 
</DOC>